Asia-Pacific Multicancer Screening Market - Analysis and Forecast, 2023-2032

1.1 Product Definition
1.2 Inclusion and Exclusion Criteria
1.3 Market Scope
1.3.1 Scope of the Study
1.3.2 Key Questions Answered in the Report
1.4 Research Methodology
1.4.1 Asia-Pacific Multicancer Screening Market: Research Methodology
1.4.2 Data Sources
1.4.3 Market Estimation Model
1.4.4 Criteria for Company Profiling

2.1 Market Overview
2.2 Multicancer Screening Workflow Analysis
2.3 Market Footprint and Growth Potential
2.4 Future Potential
2.5 COVID-19 Impact on the Market

3.1 Patent Analysis
3.1.1 Patent Filing Trend
3.1.2 Patent Analysis (by Country)
3.1.3 Patent Analysis (by Region)
3.2 Reimbursement Scenario
3.3 Supply Chain Analysis
3.4 Pricing Analysis (by Test Type)

4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
4.4 Market Challenges
4.4.1 Lack of Awareness about the Multicancer Screening Tests
4.4.2 Too Costly to be Used as Preventive Care
4.5 Market Opportunities
4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
4.5.2 New Biomarkers being Discovered Regularly

5.1 Key Strategies and Developments
5.1.1 Mergers and Acquisitions
5.1.2 Synergistic Activities
5.1.3 Product Launches and Upgradations
5.1.4 Funding and Expansion
5.2 Market Share Analysis (2022)
5.3 Growth-Share Analysis (2022)
5.3.1 Growth-Share Analysis (by Technology)

6.1 Overview
6.2 Asia-Pacific
6.2.1 China
6.2.2 Japan
6.2.3 India
6.2.4 Australia
6.2.5 South Korea
6.2.6 Rest-of-Asia-Pacific

7.1 Overview
7.2 Market Value Chain of Multicancer Screening Market
7.3 Multicancer Screening Ecosystem Active Players
7.4 Burning Rock DX
7.4.1 Company Overview
7.4.2 Role of Burning Rock DX in the Asia-Pacific Multicancer Screening Market
7.4.3 Key Competitors of the Company
7.4.4 Business Strategies
7.4.5 Analyst Perspective
7.5 Genecast Biotechnology Co., Ltd
7.5.1 Company Overview
7.5.2 Role of Genecast Biotechnology Co., Ltd in the Asia-Pacific Multicancer Screening Market
7.5.3 Key Competitors of the Company
7.5.4 Analyst Perspective
7.6 Konica Minolta, Inc. (Ambry Genetics.)
7.6.1 Company Overview
7.6.2 Role of Konica Minolta, Inc. (Ambry Genetics.) in the Asia-Pacific Multicancer Screening Market
7.6.3 Key Competitors of the Company
7.6.4 Financials
7.6.5 Analyst Perspective

Figure 1: Asia-Pacific Multicancer Screening Market, $Billion, 2022 and 2032
Figure 2: Share of Asia-Pacific Multicancer Screening Market (by Test Type), $Billion, 2021 and 2032
Figure 3: Share of Asia-Pacific Multicancer Screening Market (by Sample), $Billion, 2021 and 2032
Figure 4: Share of Asia-Pacific Multicancer Screening Market (by Cancer Type), $Billion, 2021 and 2032
Figure 5: Share of Multicancer Screening Market (by Region), 2022
Figure 6: Asia-Pacific Multicancer Screening Market Segmentation
Figure 7: Asia-Pacific Multicancer Screening Market: Research Methodology
Figure 8: Primary Research Methodology
Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
Figure 10: Top-Down Approach (Segment-Wise Analysis)
Figure 11: Multicancer Screening Workflow, End User Perspective
Figure 12: Multicancer Screening Workflow, Laboratory Technician Perspective
Figure 13: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
Figure 14: COVID-19 Impact
Figure 15: Asia-Pacific Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
Figure 16: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
Figure 17: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
Figure 18: Supply Chain Analysis of the Multicancer Screening Market
Figure 19: Asia-Pacific Multicancer Screening Market Dynamics
Figure 20: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
Figure 21: Liquid Biopsy vs. Tissue Biopsy
Figure 22: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
Figure 23: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
Figure 24: Lead-Time Bias in Cancer Screening
Figure 25: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
Figure 26: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
Figure 27: Share of Key Developments and Strategies, January 2020-January 2023
Figure 28: Synergistic Activities Share (by Company), January 2020- January 2023
Figure 29: Product Launches and Upgradations (by Company), January 2020-January 2023
Figure 30: Market Share Analysis for Asia-Pacific Multicancer Screening Market, $Billion, 2022
Figure 31: Growth-Share Analysis of the Asia-Pacific Multicancer Screening Market (by Technology), 2022
Figure 32: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
Figure 33: Multicancer Screening Market (by Region), $Billion, 2021-2032
Figure 34: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
Figure 35: Asia-Pacific Multicancer Screening Market Share (by Country), $Million, 2021-2032
Figure 36: China Multicancer Screening Market, $Million, 2021-2032
Figure 37: Japan Multicancer Screening Market, $Million, 2021-2032
Figure 38: India Multicancer Screening Market, $Million, 2021-2032
Figure 39: Australia Multicancer Screening Market, $Million, 2021-2032
Figure 40: South Korea Multicancer Screening Market, $Million, 2021-2032
Figure 41: Rest-of-Asia-Pacific Multicancer Screening Market, $Million, 2021-2032
Figure 42: Multicancer Screening Market, Total Number of Companies Profiled
Figure 43: Multicancer Screening Market: Value Chain
Figure 44: Burning Rock DX: Product Portfolio
Figure 45: Genecast Biotechnology Co., Ltd: Product Portfolio
Figure 46: Konica Minolta, Inc. (Ambry Genetics.): Product Portfolio
Figure 47: Konica Minolta, Inc. (Ambry Genetics.): Overall Financials, $Million, 2019-2021
Figure 48: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Segment), $Million, 2019-2021
Figure 49: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Region), $Million, 2019-2021
Figure 50: Konica Minolta, Inc. (Ambry Genetics.): R&D Expenditure, $Million, 2019-2021

Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Asia-Pacific Multicancer Screening Market
Table 2: Technological Trends in Asia-Pacific Multicancer Screening Market
Table 3: Average Prices of Multicancer Screening Kits Calculation
Table 4: Likert Scale
Table 5: Impact Analysis of Market Drivers
Table 6: Impact Analysis of Market Challenges
Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
Table 8: Top Multicancer Screening Tests and Their Costs ($)
Table 9: Asia-Pacific Multicancer Screening Market, Pipeline Tests
Table 10: Cancers and Their Most Common Biomarker Tests